Jade Biosciences, Inc. JBIO
14.42
(0.31)
(2.10%)
as of 25 Sep
- Market cap
- $936.8M
- P/E
- 0.0×
Follow JBIO
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 5.35 | 2.64 | 68.37 | 16.90 | 7.04 | 5.81 | 21.09 |
Net Debt/EBITDA |
— | 0.30 | 0.51 | 7.26 | 2.38 | 1.45 | (1.08) | 2.94 |
Debt/Assets |
0.00% | 71.14% | 0.00% | 0.22% | 0.52% | 0.00% | 147.80% | 0.00% |
Debt/Equity |
— | (0.69) | 0.00 | 0.00 | 0.01 | 0.00 | (2.30) | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.84 | 0.82 | 1.19 | 0.76 | 0.75 | 0.48 | 0.95 |
Capex/Depreciation |
— | — | 0.00 | (5.84) | 0.23 | 0.05 | 0.00 | 0.26 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 39.21% | 113.16% | (28.87%) | (34.44%) | (63.95%) | (149.96%) | (70.09%) | |
| — | (189.53%) | (233.59%) | (25.50%) | (33.16%) | (57.49%) | (46.93%) | (47.39%) | |
ROIC |
— | 0.00% | 0.00% | (265.23%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (116.56%) | (326.79%) | (13.35%) | (41.56%) | (70.66%) | (81.47%) | (30.12%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (403.04) | (1,138.99) | (78.71) | (56.37) | (75.84) | (7.17) | (3.03) |
Cash per Share |
— | 509.28 | 662.75 | 477.67 | 185.26 | 163.14 | 21.99 | 10.72 |
Shareholders Equity per Share |
— | (527.97) | (1,933.91) | 492.06 | 181.71 | 145.84 | (14.83) | 10.60 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (527.97) | (1,933.91) | 492.06 | 181.71 | 145.84 | (14.83) | 10.60 |
Free Cash Flow |
— | (2.78) | (7.86) | (27.58) | (39.32) | (56.92) | (22.61) | (94.88) |
Working Capital |
— | 2.86 | 2.90 | 171.78 | 123.71 | 106.60 | 57.66 | 332.28 |
Capital Expenditures |
— | — | — | (0.18) | (0.19) | (0.14) | — | (0.20) |
Net Current Asset Value |
— | (3.64) | (13.38) | 171.39 | 122.94 | 106.27 | (49.94) | 331.55 |
| Other line items | ||||||||
Quick Ratio |
— | 5.35 | 2.58 | 65.64 | 16.61 | 6.94 | 5.78 | 20.33 |
Depreciation/Fixed assets |
— | — | 0.03 | 0.17 | (3.48) | (10.28) | (327.67) | (4.46) |
Cash ROIC |
— | (117.29%) | 90.05% | (8.11%) | (15.34%) | (24.61%) | (17.38%) | (14.19%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (403.04) | (1,138.99) | (78.19) | (56.09) | (75.65) | (7.17) | (3.02) |
Capex per Share |
— | 0.00 | 0.00 | (0.52) | (0.28) | (0.19) | 0.00 | (0.01) |
Average Payables |
— | 0.58 | 0.58 | 0.91 | 1.89 | 2.49 | 1.84 | 1.72 |
Average Assets |
— | 1.76 | 4.11 | 90.04 | 155.33 | 131.36 | 100.11 | 211.29 |
Average Common Equity |
— | (8.49) | (8.49) | 79.54 | 149.58 | 118.10 | 31.33 | 142.86 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates